HECN30227 injection(SAD)

Phase 1

Sunshine Lake Pharma Co., Ltd.

HECN30227 injection(SAD) is one of 3 therapeutic programs targeting HBV Infection. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

HBV InfectionRecruiting

HBV InfectionPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in HBV Infection

#DrugCompanyPhaseTrials

Epivir

GGlaxo Dba Glaxosmithkline

Approved

1 2

Intron a

Sanofi

Phase 3

1 3

HECN30227 injection(SAD)

Sunshine Lake Pharma Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

HBV Infection

NCT07771140

Clinical

Trials by Indication[1]

HBV Infection1 trial

A Randomized, Double-blind, Placebo-controlled, Dose-escalating Phase I Trial With Single and Multiple Dosing to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of HECN30227 Injection in Healthy Volunteers and Subjects With Chronic Hepatitis B

Recruiting· Sunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd.·Phase 1·NCT07771140·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HECN30227 injection(SAD). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for HECN30227 injection(SAD). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sunshine Lake Pharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Sunshine Lake Pharma Co., Ltd.

HECN30227 injection(SAD)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

HBV Infection1 trial

References

Drug Info

Quick Facts

Related News